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Abstract
Background: Supplementation of nutritional deficiencies helps to improve immune function and resistance to infections
in malnourished subjects. However, the suggested benefits of dietary supplementation for immune function in healthy
well nourished subjects is less clear. Among the food constituents frequently associated with beneficial effects on immune
function are micronutrients such as vitamin C, vitamin E, β-carotene and zinc, and colostrum. This study was designed
to investigate the effects these ingredients on immune function markers in healthy volunteers.
Methods: In a double-blind, randomized, parallel, 2*2, placebo-controlled intervention study one hundred thirty-eight
healthy volunteers aged 40–80 y (average 57 ± 10 y) received one of the following treatments: (1) bovine colostrum
concentrate 1.2 g/d (equivalent to ~500 mg/d immunoglobulins), (2) micronutrient mix of 288 mg vitamin E, 375 mg
vitamin C, 12 mg β-carotene and 15 mg zinc/day, (3) combination of colostrum and micronutrient mix, or (4) placebo.
Several immune function parameters were assessed after 6 and 10 weeks. Data were analyzed by analysis of variance.
Groups were combined to test micronutrient treatment versus no micronutrient treatment, and colostrum treatment
versus no colostrum treatment.
Results: Overall, consumption of the micronutrient mix significantly enhanced delayed-type hypersensitivity (DTH)
responses (p < 0.05). Adjusted covariance analysis showed a positive association between DTH and age. Separate analysis
of younger and older age groups indicated that it was the older population that benefited from micronutrient
consumption. The other immune function parameters including responses to systemic tetanus and oral typhoid
vaccination, phagocytosis, oxidative burst, lymphocyte proliferation and lymphocyte subset distribution were neither
affected by the consumption of micronutrients nor by the consumption of bovine colostrum concentrate.
Conclusion:  Consumption of bovine colostrum had no effect on any of the immune parameters assessed. The
micronutrient mix enhanced cellular immunity as measured by DTH, with an increased effect by incremental age, but did
not affect any of the other immune parameters measured. Although correlations between decreased DTH and enhanced
risk of certain infection have been reported, it remains unclear whether and enhanced DTH response actually improves
immune defense. The present data suggests that improvement of immune parameters in a population with a generally
good immune and nutritional status is limited and that improvement of immune function in this population may be
difficult.
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Background
Supplementation of nutritional deficiencies helps to
restore immune function and contributes to increased
resistance to infections in malnourished subjects [1]. The
literature is less clear however, on the suggested benefits
of dietary supplementation for immune function in
healthy well nourished subjects without overt signs of
compromised immune function. Still, there is strong
interest among consumers for food products that can help
optimize their immune system and numerous products
claiming this, are on the market. Among the food constit-
uents frequently associated with beneficial effects on
immune function are micronutrients such as vitamin C,
vitamin E, β-carotene and zinc, and also the first milk pro-
duced after parturition (colostrum).
Studies suggest that vitamin C may enhance immune
functions such as phagocytosis, neutrophil chemotaxis
and lymphocyte proliferation [2-4], but contrasting find-
ings have also been published [5-7].
Vitamin E has been shown to enhance antibody responses
to hepatitis B- and tetanus vaccination [8] and to increase
delayed type hypersensitivity (DTH) response in healthy
elderly people [8,9], β-carotene can affect immune func-
tion after conversion to vitamin A, but also influences
immune activity beyond its pro-vitamin A activity [10].
The most consistent findings of β-carotene activity on
immune function are enhanced NK cell activity and TNF-
α production [11-13]. Supplementation with 15–25 mg
zinc per day in elderly people showed no improvement of
the DTH response, lymphocyte proliferation or NK cell
activity [14-16]. Higher doses (> 100 mg/day) may
improve certain immune aspects in elderly, although
some findings are controversial [14,17,18].
Colostrum contains high concentrations of natural
immunoglobulins (mainly IgG) that can bind and neu-
tralize pathogens in the intestinal tract, bactericidal fac-
tors such as lactoferrin, lactoperoxidase and lysozyme,
and growth factors and cytokines that may improve
immune defense and gut-barrier function [19-21]. How-
ever, data to substantiate suggested benefits of natural
colostrum are limited. Natural bovine colostrum has been
shown to stimulate in vitro phagocytic activity of leuko-
cytes from cattle [22] and human [23]. Consumption of
100 ml colostrum daily for 7 days by volunteers that were
orally vaccinated to S.typhi, resulted in more volunteers
with a high number of specific IgA secreting cells,
although the average number of specific antibody secret-
ing cells was not increased [24].
The current study was designed to investigate the efficacy
of commercially viable- and "realistically-to-consume
amounts" of bovine colostrum concentrate (Proventra®)
and a mix of micronutrients (vitamins E & C, β-carotene
and zinc) on immune function in healthy immuno-com-
petent subjects aged 40–80 y. Using a complete 2*2 facto-
rial design, subjects were supplemented with bovine
colostrum, a mixture of the micronutrients, a combina-
tion of bovine colostrum and micronutrients, or a pla-
cebo, for 10 weeks. A range of immunological markers
was measured, which were identified as relevant for
assessing immune function and comprised aspects of
innate and adaptive immune function [25]. These
included the response to tetanus and (oral) typhoid vacci-
nation, delayed-type hypersensitivity (DTH) responses,
phagocytosis, oxidative burst, lymphocyte proliferation
and lymphocyte subset distribution.
Methods
Subjects and study design
This study was conducted from September to December
2001 at the Unilever Food & Health Research Institute,
Vlaardingen, The Netherlands, after approval by the Med-
ical Ethical Committee of Unilever R&D Vlaardingen. At
an oral briefing 394 interested candidates completed a
questionnaire, resulting in 110 rejections based on exclu-
sion criteria and 21 withdrawals. Two hundred and sixty-
three subjects were invited for physical examination. One
hundred seventy seven subjects were found eligible. Two
subjects withdrew and 35 were excluded by lot. The
remaining 140 subjects were randomized to the treat-
ments. Three subjects withdrew after randomization but
before the start of the study. One subject was replaced.
Finally, one hundred and thirty-eight subjects entered the
study. Subjects were healthy, non-smoking, males and
females 40–80 y of age, with average Dutch dietary habits,
BMI ≥ 18,0 < 32,0 kg/m2, normal clinical chemistry, teta-
nus antibody titers < 700 IU/L, and plasma vitamin E lev-
els ≤ 40 μmol/L. Exclusion criteria were: known diseases,
medication affecting immune function and/or intestinal
flora, lactose intolerance, high IgE titers to bovine milk or
prior typhus vaccination. Subjects were allocated to one of
four treatment groups, stratified for gender and rand-
omized for age, basal plasma vitamin E concentrations
and titer of tetanus antibodies.
Using a complete 2*2 factorial design, subjects received:
(1) control product (2) product containing 1.2 g/d bovine
colostrum concentrate (equivalent to ~430 mg IgG), (3) a
product containing a mix of micronutrients or (4) a prod-
uct containing both the bovine colostrum concentrate
and the micronutrient mix. The active ingredients were
supplied in single serving sachets containing powdered
drinks based on skim milk powder, sugar and maltrodex-
trin. Other ingredients were citric acid, lecithin, colorant
and flavoring. The levels of active ingredients are listed in
Table 1. Bovine colostrum concentrate (Proventra®) was
obtained from GalaGen Inc.(Minnetonka MN) as a sprayNutrition Journal 2006, 5:28 http://www.nutritionj.com/content/5/1/28
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dried sterile filterable powder from the whey fraction of
non-specific bovine colostrum. The formulation was
developed at the Unilever Health Institute and produced
at Budelpack Hamont N.V./S.A. (Hamont-Achel, Bel-
gium). Participants were asked to consume one serving of
water-soluble powder dissolved in a glass of water (100
ml) at breakfast and one at dinner. The control and test
products were supplied to the participants (pre-portioned
in 20 g amounts in two flavors) every 2 weeks. Compli-
ance to dietary restrictions and test product consumption
was evaluated at 2 week intervals using a questionnaire.
Participants were instructed to maintain their habitual
diet and refrain from using supplements containing vita-
min E, vitamin C, β-carotene, zinc, pre- and probiotics
and supplements claiming to affect immune function or
gut health. Before the intervention, baseline measures
were taken of plasma micronutrient concentrations, DTH
response, vaccine-specific antibodies and ex vivo immune
functions (leukocyte subsets, phagocytosis, oxidative
burst, lymphocyte proliferation, cytokine production).
These measures were repeated after 6 weeks intervention.
Subsequently, subjects received an intra-muscular tetanus
vaccine and an oral typhoid vaccine. The dietary interven-
tion was continued until week 10 and specific responses
to the vaccines were measured in week 8 and 10. In addi-
tion, a final measurement of the plasma concentrations of
vitamin E, and C, and β-carotene was made at week 10.
Blood and saliva sampling
Fasted blood samples were obtained at baseline, week 6,
week 8 and week 10 by venipuncture. Aliquots of plasma
and serum were stored at -70°C until further analysis.
Plasma for vitamin C analysis was mixed with metaphos-
phoric acid and stored at -20°C. Saliva stimulated by
chewing on parafilm was collected at baseline, week 8 and
week 10. Samples were kept on ice, centrifuged 15 min-
utes at 3000 g at 4°C to pellet debris. Supernatants were
aliquoted and stored at -70°C until further analysis.
Vaccination
After 6 weeks, subjects were vaccinated for tetanus (single
i.m. injection of tetanus toxoid vaccine, Te Anatoxal
Berna, Primmed BV, Almere, NL) and typhoid (three oral
doses on alternate days of Vivotif Berna, Primmed BV,
Almere, NL), to assess both systemic and mucosal
immune responses. Vaccine-specific antibodies were
determined at baseline and weeks 8 and 10 (i.e. 2 and 4
weeks after vaccination). Proliferative responses to the
vaccine antigen were determined at baseline and week 10.
Tetanus specific antibody titers were determined by ELISA
(Tetanus toxoid Sensitive IgG antibody test, Gamma Ang-
leur-Liege, Belgium) according to manufacturer's instruc-
tions. Subjects with ≥ 4-fold increase over baseline were
classified as responders to the tetanus vaccination. Anti-
bodies to S.typhi Ty21a LPS were determined by ELISA at
the Berna Swiss Serum and Vaccine Institute, Berne, Swit-
zerland according to a standard operating procedure. Sub-
Table 1: Composition of study products1. Content of the study products was determined at baseline and for micronutrients E and C 
and β-carotene also at week 6 and week 10. Of each group, both mango- and orange flavored products were analyzed. Data are 
presented as the contents of 2 packages, which represents a daily dose.
Control Colostrum Micronutrients Colostrum + Micronutrients
target orange mango orange mango orange mango orange mango
Energy* (kJ) 628 627 626 625 625 624 623 622
Moisture (%)* 2.6 ± 0.1 2.25 ± 0.25 2.65 ± 0.15 3.15 ± 0.25 2.3 ± 0.1 2.5 ± 0.2 3.1 ± 0.1 3.1 ± 0.1
Fat (%)* 5.5 ± 0.1 5.45 ± 0.05 5.5 ± 0.1 5.9 ± 0.3 6.2 ± 0 6.4 ± 0.1 6.6 v 0.2 6.2 ± 0
Protein (%)* 17.3 ± 0.1 17.6 ± 0.1 16.9 ± 0.1 17.1 ± 0.25 17.1 ± 0.2 16.9 ± 0.15 16.9 ± 0.15 17.2 ± 0.3
IgG (mg)*2 - - 422 466 - - 430 416
Vitamin E (mg)
B a s e l i n e 2 0 0 - ---3 3 3  ±  8 3 1 4  ±  1 . 4 2 9 6  ±  8 . 8 2 9 3  ±  1
w e e k  6 - ---2 7 2  ±  2 . 7 2 7 8  ±  4 . 2 2 6 8  ±  0 . 5 2 6 4  ±  0 . 3
w e e k  1 0 - ---2 8 1  ±  0 . 3 2 7 9  ±  2 . 8 2 9 0  ±  0 . 8 2 8 6  ±  0 . 2
β-carotene (mg)
B a s e l i n e 1 0 - ---1 2 . 6  ±  0 . 2 1 3 . 2  ±  0 . 5 1 2 . 3  ±  0 . 4 1 2 . 2  ±  0 . 4
w e e k  6 - ---1 1 . 0  ±  0 1 0 . 8  ±  0 . 2 1 1 . 2  ±  0 , 2 1 0 . 8  ±  0 . 4
w e e k  1 0 - ---1 2 . 7  ±  0 . 4 1 2 . 9  ±  0 . 1 1 2 . 6  ±  0 . 2 1 2 . 1  ±  0 . 2
Vitamin C (mg)
B a s e l i n e 2 5 0 - ---3 6 5  ±  8 3 5 1  ±  6 3 6 9  ±  6 3 8 5  ±  1 0
w e e k  6 - ---3 9 5  ±  1 5 3 8 1  ±  4 3 6 4  ±  1 7 3 4 5  ±  2 7
w e e k  1 0 - ---3 8 2  ±  6 3 8 6  ±  4 3 8 2  ±  5 3 9 0  ±  3
Z i n c  ( m g )  * 1 5 - ---1 4 . 6  ±  2 . 0 4 1 5 . 3  ±  1 . 8 3 1 5 . 0 9  ±  0 . 3 1 6 . 0 4  ±  1 . 2 8
* parameters identified by * were determined at baseline only. - not determined.
1 data are expressed as mean ± SD, except for (calculated) energy and IgG, which are given as means.
2IgG was determined by radioimmunodiffusion by Galagen Inc. Mean concentrations of 2 tests were reported without SD.Nutrition Journal 2006, 5:28 http://www.nutritionj.com/content/5/1/28
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jects with ≥ 2-fold increase over baseline for
postvaccination titers > 1 E.U/ml, or ≥ 3-fold increase over
baseline for postvaccination titers < 1 E.U/ml were classi-
fied as responders [26] (Dr.J. Que, Swiss Vaccine Institute,
personal communication)
Delayed-type hypersensitivity (DTH) response
Delayed-type recall responses were assessed at baseline
and after 6 weeks intervention using the Multitest CMI
applicator from Pasteur Mérieux (Lyon, France) for simul-
taneous intra-cutaneous application of six antigens (Teta-
nus, Diphteria, Streptococcus group C, Candida albicans,
Trichophyton mentagrophytes, Proteus mirabilis). Tuber-
culin was removed from the applicator to avoid interfer-
ence with tuberculosis surveillance. Forty-eight ± 3 hours
after application, the number of indurations and indura-
tion diameters were recorded. The DTH response of each
subject was calculated as the number of positive (> 2 mm)
responses out of the six test antigens and the sum of diam-
eters of all positive responses.
Plasma levels of micronutrients
Micronutrient concentrations were determined in plasma
samples collected at baseline, week 6 and week 10. α-
Tocopherol and β-carotene levels were determined by
HPLC, performed at Analytico Medinet B.V (Breda, Neth-
erlands) according to standard procedures. Vitamin C was
determined enzymatically on EDTA plasma samples
(stored frozen with 4.5 % MPA) according to Vuilleumier
and Keck (1989) adapted for use on a Packard Multiprobe
ll HT analyzer.
Leukocyte subsets
Leukocyte subsets were determined in heparinized whole
blood at baseline, week 6 and week 10 using a standard-
ized four-color flowcytometric method (TetraCHROME,
Beckman Coulter Nederland BV, Mijdrecht with added
CD16-RD1 from Immunotech). Absolute numbers and
percentages of leukocytes (CD45+), T cells (CD45+/
CD3+), helper T cells (CD3+/CD4+/CD45+), cytotoxic/
suppressor T cells (CD3+/CD8+/CD45+), precursor B
cells and B cells (CD19+/CD45+) and NK cells (CD3-/
(CD56/CD16)+/CD45+) were determined. Samples were
analyzed on the Coulter EPICS XL flowcytometer (Beck-
man Coulter Nederland BV, Mijdrecht) using fully auto-
mated tetraONE SYSTEM software (Beckman Coulter
Nederland BV, Mijdrecht).
Phagocytosis and oxidative burst
Phagocytic activity and oxidative burst were determined
in heparinized whole blood at baseline and week 6. For
phagocytosis, 50 ul of whole blood was incubated at
37°C for 5 minutes with FITC-labeled E.coli (Phagotest®,
Orpegen, Heidelberg, Germany), or for 10 minutes with
unlabeled E.coli (Phagoburst®, Orpegen, Heidelberg, Ger-
many) according to the manufacturers instructions. Con-
trol samples were incubated with bacteria on ice. For
oxidative burst, samples were subsequently incubated
with dihydrorhodamine 123 substrate for 10 minutes. For
both assays erythrocytes were lysed and samples were
fixed and stained with propidium iodide. Analysis was
performed by flowcytometry (Coulter EPICS XL, Beckman
Coulter Nederland BV, Mijdrecht). Leukocytes were gated
into monocyte and granulocyte populations according to
FSC/SSC profile. The percentage of cells responding with
phagocytosis/oxidative burst in these populations and the
mean fluorescence of these cells were determined.
Lymphocyte proliferation
Mitogen-induced lymphocyte proliferation was assessed
in 10* diluted whole blood cultures at baseline and week
6. Samples were incubated in quadruplicate with a mix-
ture of anti-CD3 and anti-CD28 monoclonal antibodies
(PeliCluster, Sanquin Reagents, Amsterdam, the Nether-
lands) at final concentrations of 0, 0.1 and 1 μg/ml.
Antigen-specific proliferation was assessed in PBMC cul-
tures (1.106 PBMC/ml in 10 % autologous plasma) at
baseline and week 10. Cells were incubated in quadrupli-
cate cultures with tetanus toxoid (NIBSC, Hertfordshire,
UK) at final concentrations of 0, 1, 2.5 and 5 lfu/ml or
with heat-inactivated S.typhi Ty21a cells at 0, 0.1*106,
1*106 and 5*106 cells/ml. Bacterial cells were cultured
from the oral vaccine capsule (Vivotif Berna, Primmed BV,
Almere, NL) by resuspending the capsule contents in ster-
ile water and plating onto BHI agar plates for single col-
ony isolation. An isolated colony was then expanded in
Luria broth, heat inactivated and stored at 4°C until use.
Desired  S.typhi  Ty21a concentrations were prepared in
RPMI culture medium and incubated with PBMC.
Cultures were incubated for 3 (mitogenic) or 6 days (anti-
gen specific) at 37°C, 5% CO2. Eighteen hours before the
end of the incubation periods, 0.4 μCi methyl-3H-thymi-
dine (Amersham Pharmacia, Buckinghamshire, UK) was
added per well. Incorporated 3H-thymidine was measured
in a β-scintillationcounter (Microbeta Trilux scintillation-
counter, Wallac, Turku, Finland).
Statistics
The power of the study was based on a study by Meydani
et al [8]. In this study 200 mg d, l-α-tocopherol increased
the antibody response to tetanus toxoid vaccine 1.7-fold
(P = 0.04). From these data the variance of the natural log
was calculated to be 0.8. It is estimated that a difference of
1.5 would indicate a significant increase in antibody titers.
In a 2 × 2 factorial design (with A and B as factors), 35 vol-
unteers per group (70 per level of A or B) would be suffi-
cient to detect a 1.53-fold increase in response to tetanusNutrition Journal 2006, 5:28 http://www.nutritionj.com/content/5/1/28
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toxoid vaccine (power of 0.8, alpha = 0.05). Therefore, a
total of 140 subjects were recruited.
Data were analyzed by analysis of variance with colostrum
treatment, micronutrient treatment, cohorts and gender
as factors. As in none of the tested parameters a significant
interaction between colostrum and micronutrient treat-
ment was found, groups were combined to test micronu-
trient treatment versus no micronutrient treatment, and
colostrum treatment versus no colostrum treatment.
Occasionally individual datapoints were missing due to
laboratory error or missing samples. The correct numbers
on which statistical analyses were based are provided with
the corresponding datasets.
Results are presented as least square means (LSM) with
95% confidence interval (95% CI) for the four treatment
groups. The p-values of the statistical analyses are based
on the combination of the groups (2*2 factorial design).
A p-value < 0.05 was considered significant. The distribu-
tions of the response to vaccination (TT IgG and Ty21a
IgG and IgA) were skewed, therefore, natural logarithm-
transformed values for these variables were used for statis-
tical testing. The delta compared to the baseline values of
these parameters was expressed as a factor.
Covariance-analysis, adjusted for age, gender, treatment,
cohort and interaction terms between age and treatments
was used to evaluate the association between age and
immune parameters. To show the effect of age, we subdi-
vided the group in two age groups, using the median age
of 56 years as cut-off point. All analysis were performed
using the SAS statistical package version 8.2 (SAS institute,
NC, US).
Results
Composition of test products
The average amounts of active ingredients were compara-
ble between the individual batches, were higher than the
target levels and remained stable over the time course of
the study (Table 1).
Baseline characteristics, randomization, and compliance
Four subjects dropped out of the study for reasons unre-
lated to the intervention. One of these subjects dropped
out after 6 weeks, still leaving a complete data set except
for the vaccination-related measurements. During a blind
review 4 more volunteers were excluded from the analyses
due to body weight loss > 10 kg during the study, number
of B-cells vastly exceeding reference range, non-compli-
ance and illness, respectively.
Characteristics of the 131 subjects included in the analysis
are given in Table 2. Average BMI, age, vitamin E concen-
trations and response to tetanus vaccination were similar
in all groups. Of the subjects completing the study 68%
were women and the average age was 57 ± 10 years. The
overall compliance was good, 92% of the volunteers con-
sumed more than 98 % of the supplied products. One per-
son did not consume 14 packages of the total of 140. This
person was removed from the dataset in the blind review.
Plasma concentrations of micronutrients
At baseline, plasma concentrations of vitamin E & C and
β-carotene were comparable between the groups, i.e. ~27
μmol/L for α-tocopherol, ~0.5 μmol/L for β-carotene and
~37 μmol/L for vitamin C. At week 6, α-tocopherol con-
centrations had increased by more than 90 %, vitamin C
by more than 70 % and β-carotene over 900 % (to ~5.7
μmol/L) in the groups consuming the micronutrient con-
taining drinks (P < 0.001 for all), whereas no change was
observed in the two non-micronutrient groups (Figure 1).
All concentrations seemed to plateau by week 6 as no fur-
ther increase was observed after 10 weeks intervention.
Simultaneous consumption of colostrum did not affect
the concentrations of these micronutrients in plasma.
Response to vaccination
As expected, tetanus-specific IgG increased markedly after
vaccination. Compared to baseline, titers were 17-fold
increased in the control group, 23-fold in micronutrient
group, 27-fold in colostrum group and 37-fold in micro-
nutrient + colostrum group 2 weeks after vaccination
(week 8 of the intervention) (Table 3). However, none of
the treatments significantly affected the mean titers, the
percentage of vaccine-responders (81%, 91%, 94% and
97% at week 10 for control, colostrum, micronutrient,
micronutrient + colostrum, respectively), or the mean tit-
ers of the responders (data not shown).
After the oral typhus vaccination, specific IgG and IgA tit-
ers in serum were increased in all groups 2 weeks after vac-
cination (week 8 of the intervention) after which titers
tended to decrease by 4 weeks after vaccination (week 10
of the intervention). The specific IgG antibody titers were
significantly higher in the micronutrient groups com-
pared to the non-micronutrient groups, but this signifi-
cant difference was already present at baseline and could
therefore not be attributed to the treatments (Table 3).
Increase compared to baseline values was comparable in
all groups and treatments did also not significantly affect
the percentage of responders (74%, 75%, 60% and 70%
for IgG and 42%, 64%, 53% and 59% for IgA at 2 weeks
after vaccination for control, colostrum, micronutrient,
micronutrient + colostrum, respectively), or the mean titer
of the responders (data not shown). Typhus-specific sali-
vary IgA was only found in very few subjects and only 4
out of the 129 tested individuals could be marked as
responder based on salivary IgA responses (data not
shown).Nutrition Journal 2006, 5:28 http://www.nutritionj.com/content/5/1/28
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DTH-response
The DTH response measured as the number of positive
indurations increased in all groups. In the micronutrient
group the average number (+CI) increased from 1.05
(0.72 – 1.38) to 1.73 (1.28 – 2.18) at week 6, in the micro-
nutrient +colostrum group from 1.11 (0.80 – 1.42) to
1.62 (1.20 – 2.04), in the colostrum group from 1.00
(0.68 – 1.31) to 1.33 (0.91 – 1.76) and in the control
group from 0.73 (0.39 – 1.06) to 0.85 (0.39 – 1.30). Both
the absolute values at week 6 as well as the increase com-
pared to baseline, were significantly different between the
micronutrient and the non-micronutrient groups (p =
0.009 and p = 0.031, respectively).
The cumulative induration diameter tended to increase in
all groups although neither the absolute values at week 6
nor the increases compared to baseline were significantly
different between the micronutrient and the non-micro-
nutrient groups (p = 0.068 and p = 0.16 respectively).
Covariance-analysis, adjusted for age, gender, cohort,
treatment and interaction terms between age and treat-
ment, indicated a positive association between DTH
response and age. To show this association, we subdi-
vided the group in two age groups, using the median age
of 56 years as cut-off point. Both the number of positive
indurations and the cumulative induration diameter were
significantly different between the micronutrient group
and the non-micronutrient group in the older age group
with p < 0.05 but not in the younger (see Figure 2).
Leukocyte subsets
A small but significant (p < 0.05) decrease in the percent-
age of B cells was observed at 10 weeks in the micronutri-
ent-groups compared to the non-micronutrient groups
(LSM (CI) for control, colostrum, micronutrient, micro-
nutrient + colostrum were 14.6 (12.9–16.4), 13.2 (11.5–
15.0), 11.8 (10.0–13.6), 12.1(10.4–13.8), respectively).
As there were no related observations made, the biological
relevance of this observation is unclear and we therefore
regard this as an incidental finding. Changes in all other
leukocyte populations, i.e. total leukocytes, T cells, helper
T cells, cytotoxic/suppressor T cells, NK cells and NK-T
cells were limited and did not differ between groups,
either in absolute numbers or percentages (data not
shown). The observed values were well within normal
ranges.
Phagocytosis and oxidative burst
Consumption of colostrum and/or micronutrient-con-
taining test products did not affect the percentage of
phagocyting granulocytes when whole blood taken from
these subjects was ex vivo stimulated with non-opsonised
or opsonised E coli, nor did it affect phagocyting activity
per cell as indicated by the mean fluorescence (Table 4).
Retrospective power calculation indicated that the study
had sufficient power to allow detection of changes in
phagocyting granulocytes of > 4 %. The oxidative burst in
the phagocyte population as elicited by an E. coli -chal-
lenge, was also not affected (data not shown).
Table 2: Baseline characteristics of subjects who completed the study
Total Control Colostrum Micronutrients Micronutrients + colostrum
Gender, n
Total 131 31 33 32 35
Men 42 10 11 10 11
Women 89 21 22 22 24
Age, years
Total 56.7 ± 10.0 56.0 ± 10.1 56.8 ± 10.2 57.5 ± 10.1 56.3 ± 9.9
Men 61.4 ± 10.1 57.7 ± 9.9 62.4 ± 10.9 61.9 ± 11.4 63.4 ± 8.5
Women 54.4 ± 9.2 55.2 ± 10.3 54.1 ± 8.9 55.5 ± 9.1 53.0 ± 8.8
BMI, kg/m2
Total 25.3 ± 2.7 25.1 ± 3.2 25.4 ± 2.50 24.9 ± 2.5 25.6 ± 2.5
Men 26.0 ± 2.6 26.5 ± 3.4 26.0 ± 2.3 26.0 ± 2.3 25.5 ± 2.5
Women 24.9 ± 2.7 24.5 ± 3.1 25.1 ± 2.6 24.3 ± 2.5 25.6 ± 2.5
Vitamin E, μmol/L
Total 27.1 ± 7.2 27.3 ± 10.0 27.9 ± 6.3 26.9 ± 4.5 26.4 ± 7.2
Men 28.1 ± 9.7 33.6 ± 13.7 24.5 ± 6.6 25.8 ± 3.8 28.9 ± 10.5
Women 26.6 ± 5.6 24.3 ± 6.0 29.6 ± 5.6 27.4 ± 4.7 25.3 ± 4.9
Tetanus titers, IU/L
Total1 -1 2 6
(90.2 – 175)
154
(111 – 212)
147
(105 – 206)
138
(101 – 189)
Data are represented as mean ± SD
1 Tetanus titers were determined at the screening examination, mean (95% CI)Nutrition Journal 2006, 5:28 http://www.nutritionj.com/content/5/1/28
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Lymphocyte proliferation
Whole blood cultures stimulated with the mitogenic stim-
ulus anti-CD3/CD28 demonstrated the expected relation-
ship between stimulus concentration and proliferative
response. A few significant differences were observed
between the groups, but these were already apparent at
baseline and the treatments did not affect the mitogenic
proliferative responses as assessed at week 6 (data not
shown). Stimulation of PBMC cultures with tetanus tox-
oid indicated the expected increase in responsiveness fol-
lowing the tetanus vaccination (at 4 weeks after
vaccination compared to baseline), but the responses
were not affected by the treatments (not shown). In con-
trast, proliferation induced by S.typhi Ty21a cells did not
increase after vaccination. Already at baseline, prolifera-
tive responses increased with increasing concentration of
S.typhi Ty21a cells, but these responses did not increase
after typhoid vaccination and were also not affected by the
treatments (not shown).
Discussion
Out of the range of immune function parameters exam-
ined, only the DTH response was positively affected by
micronutrient intervention, whereas none of the immune
parameters were affected by consumption of bovine
colostrum. Separate analyses of older versus younger sub-
jects, demonstrated that both DTH parameters, i.e.
number of positive responses and diameter of indura-
tions, were significantly enhanced in the older popula-
tion, whereas this effect was not observed in the younger
population.
The evidence for a positive effect of micronutrient supple-
mentation on DTH seems to be consistent. Other studies
have demonstrated an increase in the DTH response of
elderly after micronutrient supplementation, especially by
vitamin E [8,9]. Also β-carotene, although in higher doses,
has been described to have stimulating effects on DTH
[27].
How and if an enhanced DTH response relates to
improved resistance remains to be elucidated. Studies sug-
gest a correlation between a low DTH score and risk of e.g.
diarrhoeal disease in Kenyan children [28] septic-related
deaths in surgical patients [29] pneumonia in elderly [30]
and progression to AIDS in HIV positive individuals [31].
Interestingly, despite the more or less consistent observa-
tion that vitamin E improves the DTH response, conflict-
ing reports were published on the effect of vitamin E on
resistance to respiratory infections. One study showed
that consumption of 200 mg vitamin E daily for 15
months does not improve resistance to acute respiratory
tract infections [32]. In fact, it was shown that the severity
of respiratory tract infection was worse in vitamin E sup-
plemented groups, as well as the duration of the symp-
Plasma concentrations of vitamin C & E and β-carotene Figure 1
Plasma concentrations of vitamin C & E and β-caro-
tene. Plasma concentrations of vitamin C & E and β-caro-
tene were measured at base line, 6 and 10 weeks. Data are 
expressed as LSM (± 95% CI). Levels in the micronutrient 
groups (micronutrient group ▲ and micronutrient + colos-
trum group ) are significantly different from levels in non-
vitamin group (control ■ and colostrum group ) with ** p 
< 0.0001.
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toms. A second study by Meydani et al [33] reported a
protective effect of 200 IU daily of vitamin E for 1 year on
upper respiratory tract infections, especially the common
cold. How these observations correlate with respect to
enhanced DTH after vitamin E suppletion remains elu-
sive. Accumulation of vitamin E in tissues may account for
detrimental effects of vitamin E and vitamin-E associated
enhanced immune reactivity could either account for
worsening of symptoms or improvement of resistance to
certain infections. Alternatively, the DTH reaction may be
an immunological parameter that is not associated with
resistance to respiratory infections.
The absence of positive effects of the micronutrient mix
on other immune parameters or of the colostrum prepara-
tion on all parameters examined, may largely be
explained by the generally good health and nutritional
status of the subjects. This is illustrated by the fact that suc-
cessful immune enhancement is generally achieved in
populations with suboptimal immune function such as
elderly and athletes [34]. Interestingly, in elderly that
retain a good nutritional status, decline in immne fucn-
tion is not apparent [35,36].
In our study population the average baseline concentra-
tions of plasma vitamin E, vitamin C and β-carotene as
well as the post-intervention vitamin E and C levels were
comparable to what has been described in other studies
[8,11,27,32,37] and are indicative for a generally well-
nourished population. The observed 900% rise in plasma
β-carotene, which is higher than reported increases of
300–600% in other studies using similar doses
[11,37,38], may be explained by the fact that the test
products contained the emulsifier lecithin in a molar ratio
of ~70 relative to ß-carotene. Emulsifiers and fat from the
formulation can help form micelles, which are required
for absorption of carotenoids during lipolysis, thereby
improving the bioavailabilty of lipophilic molecules such
as ß-carotene [39-42].
Also in the older subpopulation a lower nutritional status
can not explain the observed benefit, since baseline
micronutrient concentrations were higher (vitamin E) or
similar (vitamin C and ∃-carotene) in the subjects older
than 56 years compared to the younger subjects (29.1 ±
7.6 umol/L vs 25.1 ± 6.2 umol/L, P = 0.0012 for vitamin
E). Similarly, the size of the increase in micronutrient lev-
els did not seem to correlate with the effect on the DTH
since increases were similar in both populations.
Despite a few publications indicating the stimulatory
effect of colostrum on phagocytic activity in vitro
[22,23,43], which we confirmed with human leukocytes
(data not shown), daily consumption of 1.2 g of bovine
colostrum concentrate by volunteers in the current study
did not affect ex-vivo phagocytic activity. Similarly, none
of the other investigated immune parameters were signif-
icantly influenced by colostrum consumption, although
the response to tetanus vaccination tended to be some-
what higher (p = 0.14).
Three studies have reported effects on immune function
and resistance to infections after consumption of natural
colostrum (enhanced response to oral typhoid vaccine
[24], reduced number of URTI symptoms [44], and
increased salivary IgA [45]). However, the doses of colos-
trum used in these studies were up to 60 g/day. These high
doses may be feasible in the context of severe physical
exercise for which some of these studies were designed or
for clinical nutrition, but for daily consumption by
healthy consumers only lower doses would be economi-
cally feasible.
Table 3: response to tetanus and typoid vaccination
Control (n = 31) Colostrum (n = 33) Micronutrients (n = 31) Colostrum+Micronutrients (n = 35)2
Tetanus toxoid-specific IgG levels in serum (IU/L)
Baseline 126 (90.2 – 175) 154 (111 – 212) 147 (105 – 206) 138 (101 – 189)
Week 8 2141 (1040 – 4407) 4074 (2024 – 8200) 3368 (1625 – 6982) 5131 (2579 – 10208)
Week 10 3138 (1713 – 5748) 4728 (2629 – 8500) 4206 (2282 – 7753) 5330 (3013 – 9431)
S. typhi Ty21a LPS-specific IgG in serum (E.U/mL)
Baseline3 3.37 (2.24 – 5.07) 3.93 (2.64 – 5.84) 5.39 (3.54 – 8.20) 6.48 (4.40 – 9.52)
Week 83 12.6 (9.02 – 17.6) 16.5 (12.0 – 22.8) 19.5 (13.9 – 27.5) 21.6 (15.7 – 29.6)
Week 103 10.7 (7.67 – 14.8) 14.0 (10.1 – 19.2) 16.7 (11.9 – 23.4) 18.4 (13.5 – 25.2)
S. typhi Ty21a LPS-specific IgA in serum (E.U./mL)
Baseline 1.21 (0.85 – 1.72) 1.07 (0.76 – 1.51) 1.36 (0.95 – 1.95) 1.43 (1.03 – 1.99)
Week 8 2.70 (1.89 – 3.86) 3.40 (2.40 – 4.81) 3.49 (2.42 – 5.04) 3.73 (2.65 – 5.24)
Week 10 1.80 (1.29 – 2.52) 1.86 (1.35 – 2.57) 2.24 (1.59 – 3.14) 2.20 (1.60 – 3.01)
1 values are expressed as lsmeans (95% CI).
2 n = 34 in serum at week 8, n = 33 for saliva at week 8.
3Micronutrient group (Micronutrients group and Colostrum + Micronutrients group) is significantly different from non-micronutrient group 
(Control group and Colostrum group) (P < 0.05).Nutrition Journal 2006, 5:28 http://www.nutritionj.com/content/5/1/28
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Conclusion
Low daily doses of bovine colostrum do not improve a
series of immune function parameters in healthy volun-
teers. Micronutrient suppletion of vitamins E & C, ß-caro-
tene and zinc positively affect the DTH response,
especially in elderly subjects. How this may relate to
improved resistance remains to be elucidated. Improve-
ment of other immune parameters in individuals with a
generally good immune and nutritional status may be dif-
ficult and it may take individuals with (moderately)
impaired immune function to benefit from this type of
nutritional intervention.
Competing interests
All authors are employed by Unilever who financed the
study and publication.
Delayed-type hypersensitivity response in two age groups Figure 2
Delayed-type hypersensitivity response in two age groups. DTH responses were assessed using the CMI multitest at 
baseline and at 6 weeks. Because of significant interaction between age and treatment group (p < 0.05), the population was split 
around the median age of 56 y in younger (< 56 y) and older (> 56 y) subjects. Average age of the younger subjects was 48 ± 4 
y, with a BMI of 24.5 ± 2.8, comprising 12 men and 52 women. The average age of the older subjects was 65 ± 6 y, with a BMI 
of 26.0 ± 2.3, comprising of 30 men and 36 women. Both age categories were evenly spread over the treatments with 15–19 
subjects per treatment per age category. Data are reported as LSM of the mean increase in the number of positive responses 
(A) and increase of the cumulative diameter of the positive responses (B). Responses in the micronutrient groups (micronutri-
ent (white) and micronutrient + colostrum group (hatched)) are significantly different from levels in non-vitamin group (control 
(black) and colostrum group (grey)) with * p < 0.05.
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